Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Industry

12 Sep 2022

Algernon Pharmaceuticals Receives Approval for Phase 1 DMT Study

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study...

By Microdose

Industry, Law & Politics

9 Sep 2022

Microdose Brings Psychedelics to the Concordia Summit

The Concordia Annual Summit has been bringing together heads of state, leaders of the private and NGO sectors, and new and diversified perspectives for over a decade - and for...

By Microdose

Industry

23 Aug 2022

Freedom Bio Announces $10.5M Seed Financing For Next-Gen Psychedelics

Freedom Biosciences is a clinical-stage biotechnology platform developing ketamine and psychedelic therapeutics — based on 20 years of Yale University research & Dr....

By Microdose

Psychedelic Titans

17 Aug 2022

Psychedelic Titans with Mary-Elizabeth Gifford of Psyence Group

Psychedelic Support is the leading online education and therapeutic platform in the psychedelic space advocating for mental health and wellbeing worldwide....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

20 Jul 2022

Learning From Wonderland: A Look at Psychedelics’ Top Event

Last year, Microdose provided a stomping ground for those interested and involved in the psychedelic medicine space, with over 1600 attendees, including sponsors and investors over two packed days with...

By Microdose

Industry

11 Jul 2022

In Psychedelic Investing, Long-Term Thinking Is Key

In the fast-growing field of psychedelic medicine, long-term investing is key....

By Microdose

Press Releases

17 Jun 2022

Psylo To Collaborate with NIDA to Evaluate Psylo’s Lead Candidate Drug

Psylo and NIDA will collaborate on the preclinical development and testing of Psylo’s novel compounds...

By Microdose

Events

15 Jun 2022

PsyCap Recap, May 2022: Irwin Naturals

Klee Irwin of Irwin Naturals joined us at Micrdose’s most recent Psychedelic Capital event, where he spoke of Irwin Naturals Emergence plan to help address mental health issues....

By Microdose

Industry, Press Releases

13 Jun 2022

Launch of the Psychedelic Access and Research European Alliance – PAREA

PAREA is a non-profit, multistakeholder and multidisciplinary partnership bringing together patient organizations, medical associations, scientific societies, psychedelic foundations, and the for-profit sector....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.